Haemoadsorption During Heart Transplantation

Launched by MEDICAL UNIVERSITY OF VIENNA · Feb 26, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called haemoadsorption (HA) during heart transplantation, which is a surgery to replace a damaged heart with a healthy one. The goal is to see if using HA can help reduce inflammation and improve how the body responds after the transplant. Researchers want to find out if this treatment can lower the levels of certain substances in the blood that can cause inflammation and if it can help with potential complications after the surgery, such as problems with the heart graft, difficulty breathing, or kidney issues. They will track patients for the first 120 hours after their transplant to gather important information on these effects.

To participate in this study, patients must be adults who are scheduled to have a heart transplant. However, those who are younger than 18, have certain health conditions, or are taking specific medications that suppress the immune system cannot join. Participants can expect close monitoring during and after their surgery, and their recovery will be carefully observed to see how the HA treatment impacts their overall health and recovery process. This trial is currently recruiting patients of all genders, ages 65 and older, who are eligible for heart transplantation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients undergoing heart transplantation
• Exclusion Criteria:
• • Declined informed consent
• • Age \< 18 years#
• • Receiving antileukocyte drugs
• • Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab)
• • DCD
• • Ex-vivo perfusion